Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra and tocilizumab versus standard-of-care in non-ventilated COVID-19 respiratory distress
2020-001748-24Phase 2Completed
- Sponsor
- Karolinska University Hospital
- Start
- Apr 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Standard-of-care, Anakinra (Kineret) arm and Tocilizumab (RoActemra) arm (3 arms). Primary endpoint: Time to recovery. Started Apr 2020; status: completed.
02
Drugs
anakinratocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001748-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001748-24.